Immunic, Inc. Common Stock vs. Johnson & Johnson
Johnson & Johnson (JNJ) comes out ahead, leading on 2 of 2 compared factors.
Size & Scale
| IMUX | JNJ | |
|---|---|---|
| Market Cap | $178.88 million | $663.28 billion |
| Revenue (TTM) | — | $97.93 billion |
| Net Income (TTM) | — | $21.04 billion |
JNJ leads on 1 of 1 size & scale factors.
Valuation
| IMUX | JNJ | |
|---|---|---|
| P/E Ratio | — | 31.93 |
| Price / Book | — | 7.81 |
| Price / Sales | — | 6.77 |
IMUX and JNJ split the valuation factors evenly.
Profitability
| IMUX | JNJ | |
|---|---|---|
| Net Margin | — | 21.48% |
| Return on Equity | — | 24.76% |
IMUX and JNJ split the profitability factors evenly.
Dividend
| IMUX | JNJ | |
|---|---|---|
| Dividend Yield | — | 1.95% |
| Payout Ratio | — | 62.18 |
IMUX and JNJ split the dividend factors evenly.
Risk & Sentiment
| IMUX | JNJ | |
|---|---|---|
| Short Interest | 2.84% | 0.67% |
JNJ leads on 1 of 1 risk & sentiment factors.
Dig deeper: IMUX overview, IMUX financials, JNJ overview, JNJ financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.